Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2022 Sep 13;13:1017924. doi: 10.3389/fimmu.2022.1017924

Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Chilam Chan 1, Marta Lustig 2, Niklas Baumann 2, Thomas Valerius 2, Geert van Tetering 1,, Jeanette H W Leusen 1,*,
PMCID: PMC9514090  PMID: 36177025

In the published article, there was an error in Figure 5 as published. The mitochondrion was misplaced in this figure. The corrected Figure 5 and its caption appear below

Figure 5.

Figure 5

Strategies for inhibiting myeloid checkpoints. 1) Genetic knock out of target genes involved in the inhibitory pathway. 2) Specific blocking of target checkpoint molecules with mAbs or soluble ligand-Fc fusion proteins to inhibit receptor binding and checkpoint axis activation. 3) Bispecific antibodies that target both TAA and checkpoint molecules simultaneously to avoid off-target side effects.4) Biologics that alter the structure of the target protein, preventing it from binding to the receptor, or that inhibit expression or block the target protein.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES